Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Short Interest Down 55.5% in August

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 5,662 shares, a decline of 55.5% from the August 15th total of 12,737 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 19,110 shares, the days-to-cover ratio is presently 0.3 days.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN CCEL traded down $0.03 during trading on Monday, reaching $4.37. The stock had a trading volume of 4,440 shares, compared to its average volume of 16,470. The company has a market cap of $35.22 million, a P/E ratio of -14.57 and a beta of 0.47. Cryo-Cell International has a fifty-two week low of $2.72 and a fifty-two week high of $5.01. The business’s 50-day moving average price is $3.79 and its 200-day moving average price is $3.58.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $7.78 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP boosted its position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the period. Susquehanna International Group LLP owned 0.17% of Cryo-Cell International worth $45,000 as of its most recent SEC filing. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.